A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis

Inclusion Criteria: Healthy Subjects (Parts 1 and 2) * Men and women participants must be between 18-55 years inclusive, at the time of informed consent. * Female participants must either be of non-childbearing potential or if of childbearing potential, must not be pregnant, breast feeding or lactating and use a highly effective birth control method during treatment and for 90 days following last administered dose. In addition, male partners of female subjects of childbearing potential must use highly effective contraception for 90 days following the last administered dose * Male participants who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days after their last dose of IMP. * Participants must agree not to donate semen or ova/oocytes during the study and for 90 days after the last dose of IMP. * Participants must have a body mass index (BMI) ≥ 18 and ≤ 35 kg/m2. * Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory assessments at the time of screening, as judged by the Investigator or designee. Participants with Psoriasis (Part 3) * Men and women Participants must be between 18-65 years inclusive, at the time of informed consent. * Participants must have a documented diagnosis of plaque psoriasis for ≥ 6 months prior to screening.…